NYSE:PTHN - Patheon N.V. Ordinary shares, p Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$34.98
+0.30 (1.20%)
Get New Patheon N.V. Ordinary shares, p Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PTHN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTHN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Patheon N.V. Ordinary shares, p in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $34.98.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Patheon N.V. Ordinary shares, p. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017Jefferies Financial GroupReiterated RatingHold$35.00Low
i
6/9/2017SVB LeerinkDowngradeOutperform ➝ Market Perform$31.00 ➝ $35.00Low
i
6/9/2017Raymond JamesDowngradeOutperform ➝ Mkt PerformLow
i
6/8/2017Raymond JamesReiterated RatingOutperform ➝ Market Perform$35.00Low
i
6/8/2017JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
i
5/16/2017Jefferies Financial GroupDowngradeBuy ➝ Hold$32.00 ➝ $35.00Low
i
5/15/2017Evercore ISIDowngradeOutperform$35.00Low
i
5/15/2017William BlairDowngradeOutperform ➝ Market PerformLow
i
5/15/2017Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralLow
i
3/17/2017Jefferies Financial GroupReiterated RatingBuy$33.00 ➝ $32.00Low
i
3/17/2017Robert W. BairdDowngradeOutperform ➝ Neutral$34.00 ➝ $28.00Low
i
12/21/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
11/10/2016SVB LeerinkInitiated CoverageOutperform$31.00N/A
i
9/9/2016Jefferies Financial GroupReiterated RatingBuy$33.00N/A
i
8/23/2016William BlairInitiated CoverageOutperform ➝ OutperformN/A
i
8/16/2016Credit Suisse GroupInitiated CoverageNeutral$30.00N/A
i
8/15/2016Raymond JamesInitiated CoverageOutperform$32.50N/A
i
8/15/2016Jefferies Financial GroupInitiated CoverageBuy$32.00N/A
i
8/15/2016Evercore ISIInitiated CoverageBuy$33.00N/A
i
8/15/2016William BlairInitiated CoverageOutperformN/A
i
8/15/2016Wells Fargo & CompanyInitiated CoverageOutperformN/A
i
8/15/2016UBS GroupInitiated CoverageBuy$31.00N/A
i
8/15/2016Robert W. BairdInitiated CoverageOutperform$32.00N/A
i
8/15/2016Piper Jaffray CompaniesInitiated CoverageOverweight$32.50N/A
i
8/15/2016Morgan StanleyInitiated CoverageOverweight$31.00N/A
i
8/15/2016KeyCorpInitiated CoverageOverweight$33.00N/A
i
8/15/2016JPMorgan Chase & Co.Initiated CoverageOverweight$30.00N/A
i
(Data available from 4/21/2016 forward)
Patheon N.V. Ordinary shares, p logo
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.
Read More

Today's Range

Now: $34.98
$34.98
$34.98

50 Day Range

MA: N/A

52 Week Range

Now: $34.98
$23.72
$35.13

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Patheon N.V. Ordinary shares, p?

The following equities research analysts have issued stock ratings on Patheon N.V. Ordinary shares, p in the last year:
View the latest analyst ratings for PTHN.

What is the current price target for Patheon N.V. Ordinary shares, p?

0 Wall Street analysts have set twelve-month price targets for Patheon N.V. Ordinary shares, p in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Patheon N.V. Ordinary shares, p in the next year.
View the latest price targets for PTHN.

What is the current consensus analyst rating for Patheon N.V. Ordinary shares, p?

Patheon N.V. Ordinary shares, p currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PTHN.

What other companies compete with Patheon N.V. Ordinary shares, p?

How do I contact Patheon N.V. Ordinary shares, p's investor relations team?

Patheon N.V. Ordinary shares, p's physical mailing address is Herengracht 483, Amsterdam P7, 1017BT. The company's listed phone number is 31-20-622-3243. The official website for Patheon N.V. Ordinary shares, p is www.patheon.com.